The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides

Oncology Reports

Volumn 20, Issue 1, 2008, Pages 245-252

  Zhang, Xiu Min ^a   Zhang, Yun Fei ^b   Huang, Yang ^a   Qu, Ping ^a   Ma, Bin ^a   Si, Shao Yan ^a   Li, Zeng Shan ^a   Li, Wen Xin ^a   Li, Xia ^a   Ge, Wei ^a   Hu, Pei Zhen ^a   Sui, Yan Fang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cytotoxic T lymphocyte epitope; Enzyme linked immunosorbent spot; MAGE 3; MAGE n; Tumor antigen

Indexed keywords

CANCER VACCINE; CELL ANTIGEN; EPITOPE; GENE PRODUCT; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN N DERIVED PEPTIDE; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; GAMMA INTERFERON; HLA A2 ANTIGEN; MAGEA3 PROTEIN, HUMAN; MAGEA6 PROTEIN, HUMAN; TUMOR PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIVER CELL CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MULTIGENE FAMILY; PRIORITY JOURNAL; TUMOR CELL; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; NEOPLASM; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; NEOPLASM PROTEINS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 49849104145     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.20.1.245     Document Type: Article

References (27)

1. Van den Eynde BJ and van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol 9: 684-693, 1997.
2. Thurner B, Haendle I, Roder C, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190: 1669-1678, 1999.
3. Dagher R, Long LM, Read EJ, et al: Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 38: 158-164, 2002.
4. Kawakami Y, Eliyahu S, Jennings C, et al: Recognition of multiple epitopes in the human melanoma antigen gp100 dy tumor-in-filtrating T lymphocytes associated with in vivo tumor regression. J Immunol 154: 3961-3968, 1995.
5. Zhang Y, Chaux P, Stroobant V, et al: A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol 171: 219-225, 2003.
6. Wu W, Sui YF, Ye J, et al: The cloning of tumor-associated gene MAGE in human hepatocellular carcinoma cell line. Chin J Cell Mol Immunol 18: 270-273, 2002.
7. Dong HL, Li ZS, Ye J, et al: Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma. NA: Cancer Biol Ther 3: 891-898, 2004.
8. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327, 1998.
9. Schaed SG, Klimek VM, Panageas KS, et al: T-cell responses against tyrosinase 368-376(370D) peptide in HLA(*)A0201(+) melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res 8: 967-972, 2002.
10. Salgaller ML, Marincola FM, Cormier JN and Rosenberg SA: Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56: 4749-4757, 1996.
11. Slingluff CL Jr, Yamshchikov G, Neese P, et al: Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 7: 3012-3024, 2001.
12. Scheibenbogen C, Nagorsen D, Seliger B, et al: Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides. Int J Cancer 99: 403-408, 2002.
13. Cormier JN, Salgaller ML, Prevette T, et al: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 3: 37-44, 1997.
14. Valmori D, Dutoit V, Schnuriger V, et al: Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 168: 4231-4240, 2002.
15. Knutson KL, Schiffman K and Disis ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107: 477-484, 2001.
16. Khong HT and Restifo NP: Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 3: 999-1005, 2002.
17. Parkhurst MR, Salgaller ML, Southwood S, et al: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 6157: 2539-2548, 1996.
18. Reynolds SR, Oratz R, Shapiro RL, et al: Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer 72: 972-976, 1997.
19. Ayyoub M, Mazarguil H, Monsarrat B, Van den Eynde B and Gairin JE: A structure-based approach to designing non-natural peptides that can activate antimelanoma cytotoxic T cells. J Biol Chem 274: 10227-10234, 1999.
20. Dong HL, Sui YF, Li ZS, et al: Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro. Cancer Lett 211: 219-225, 2004.
21. Gao L, Xue SA, Hasserjian R, et al: Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 75: 1429-1436, 2003.
22. Ohta K, Yamaguchi Y, Shimizu K, Miyahara E and Toge T: Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells. Anticancer Res 22: 2597-2606, 2002.
23. Mangino G, Grazia Capri M, Barnaba V and Alberti S: Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells. Int J Cancer 101: 353-359, 2002.
24. Molldrem JJ, Lee PP, Wang C, Champlin RE and Davis MM: A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 59: 2675-2681, 1999.
25. Renkvist N, Castelli C, Robbins PF and Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15, 2001.
26. Riker A, Cormier J, Panelli M, Marincola F, et al: Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126: 112-120, 1999.
27. Marincola FM, Jaffee EM, Hicklin DJ and Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74: 181-273, 2000.